Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma

by Johan Falkenius, Hemming Johansson, Rainer Tuominen, Marianne Frostvik Stolt, Johan Hansson, Suzanne Egyhazi Brage
Published 2017-08-01

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.

by Fernanda Costa Svedman, Warangkana Lohcharoenkal, Matteo Bottai, Suzanne Egyhazi Brage, Enikö Sonkoly, Johan Hansson, Andor Pivarcsi, Hanna Eriksson
Published 2018-01-01

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

by Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson
Published 2021-05-01

Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis

by Anna-Maria Georgoudaki, Kajsa E. Prokopec, Vanessa F. Boura, Eva Hellqvist, Silke Sohn, Jeanette Östling, Rony Dahan, Robert A. Harris, Mattias Rantalainen, Daniel Klevebring, Malin Sund, Suzanne Egyhazi Brage, Jonas Fuxe, Charlotte Rolny, Fubin Li, Jeffrey V. Ravetch, Mikael C.I. Karlsson
Published 2016-05-01